Cagrilintide

Mechanism

Cagrilintide is a long-acting version of amylin, a hormone naturally released by the pancreas alongside insulin after meals. It works by slowing gastric emptying, promoting satiety, and reducing glucagon secretion, helping people eat less and manage blood sugar more effectively. It is being developed as both a standalone weight loss agent and in combination with semaglutide (CagriSema) for enhanced metabolic outcomes.

Effects

APPETITE / SATIETY [Tier 1 – Human Clinical]: Cagrilintide is a long-acting acylated analog of human amylin (IAPP), engineered for once-weekly subcutaneous injection. Activates amylin receptors (AMY1, AMY2, AMY3) in the area postrema and nucleus tractus solitarius, producing central satiety signaling. Phase II data demonstrated dose-dependent weight loss up to 10.8% as monotherapy at 26 weeks. Slows gastric emptying, reduces post-prandial glucagon, promotes fullness. METABOLIC / WEIGHT LOSS [Tier 1 – Human Clinical]: CagriSema (cagrilintide + semaglutide 2.4 mg) Phase II results showed up to 15.6% weight loss at 20 weeks — exceeding semaglutide alone. Phase III REDEFINE program ongoing. The combination exploits two distinct satiety mechanisms (amylin + GLP-1) for additive/synergistic weight loss. GLYCEMIC [Tier 2 – Limited Human]: Amylin analogs reduce post-prandial glucose excursions by slowing gastric emptying and suppressing glucagon. Cagrilintide improves glycemic control, though data in type 2 diabetes specifically is still accumulating from ongoing Phase III trials. GASTROINTESTINAL [Tier 1 – Human Clinical]: Nausea is the primary side effect, consistent with amylin receptor activation and delayed gastric emptying. Generally milder than GLP-1 agonist nausea. Most nausea resolves with dose titration over 4-8 weeks. CARDIOVASCULAR [Tier 3 – Preclinical/Early]: Cardiovascular outcome data not yet available. Amylin itself has some cardiovascular signaling properties, but clinical cardiovascular benefit for cagrilintide is unproven.

Practitioner Guide

CLINICAL POSITIONING: Cagrilintide represents a new class (long-acting amylin) that will likely be prescribed primarily as CagriSema (combination with semaglutide) rather than as monotherapy. For practitioners, the key question is: "What do I do when semaglutide alone plateaus?" CagriSema is one answer — adding amylin-mediated satiety on top of GLP-1 signaling. CURRENT STATUS (2026): Phase III trials ongoing. Not yet FDA-approved. Available through some research peptide suppliers but NOT compounding pharmacies. Prescribing is limited to clinical trial settings or off-label research use. DOSING (FROM CLINICAL TRIALS): • Monotherapy dose titration: Start 0.25 mg weekly, escalate every 4 weeks through 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg. • CagriSema: Cagrilintide 2.4 mg + semaglutide 2.4 mg, both once weekly (separate injections during trials; combination pen in development). • The slow titration is critical for tolerability — rapid dose escalation causes severe nausea. PRACTITIONER INSIGHTS ON THE AMYLIN MECHANISM: • Amylin works differently from GLP-1. GLP-1 agonists reduce appetite primarily through hypothalamic GLP-1R activation and delayed gastric emptying. Amylin works through the area postrema (brainstem) — a "nausea center" adjacent to the chemoreceptor trigger zone. This explains why: (a) amylin analogs cause nausea through a partially different mechanism than GLP-1, and (b) combining both pathways can produce additive satiety without proportionally additive nausea. • Patients who plateau on semaglutide often respond to adding amylin signaling — different neural circuits for satiety. TRANSITIONING TO CAGRISEMA FROM SEMAGLUTIDE: • When CagriSema becomes available, the likely protocol: patient already on stable semaglutide 2.4 mg → add cagrilintide starting at 0.25 mg weekly → titrate cagrilintide up while maintaining semaglutide dose → expect additional 3-8% weight loss beyond semaglutide plateau. • GI side effects may re-emerge during cagrilintide titration even in patients tolerating semaglutide well. Pre-warn patients. NAUSEA MANAGEMENT: • Titrate slowly (minimum 4 weeks per dose step). Do not skip dose levels. • Small, frequent meals. Avoid large fatty meals. • Ginger (supplements or tea), peppermint tea for mild nausea. • Ondansetron (Zofran) 4 mg PRN for breakthrough nausea during titration. • Nausea usually peaks at each dose increase and resolves within 1-2 weeks. MUSCLE PRESERVATION: • Same concerns as all weight loss agents — significant caloric deficit risks lean mass loss. • Protein target: 1.0-1.2 g/kg of GOAL body weight daily minimum. Ideally 1.2-1.5 g/kg. • Resistance training 2-3x/week is NON-NEGOTIABLE during any GLP-1 or amylin-mediated weight loss. • Consider creatine monohydrate 5 g/day for additional muscle preservation support.

Dosing Protocols

Contraindications & Cautions

• hard stop — History of pancreatitis
  Amylin analogues may increase pancreatitis risk. Patients with a history of pancreatitis are at elevated risk of recurrence.
  Action: Do not use. Refer to physician for alternative therapies.
• hard stop — Medullary thyroid carcinoma or MEN2 syndrome
  Amylin analogues may carry thyroid C-cell tumor risk. Patients with personal or family history of MTC or MEN2 should not use.
  Action: Absolutely contraindicated. Do not use. Refer to oncologist/endocrinologist.
• hard stop — Pregnancy
  Amylin analogue activity poses potential embryo-fetal toxicity risk. No adequate human data.
  Action: Discontinue immediately if pregnancy is detected. Do not initiate during pregnancy.
• hard stop — Breastfeeding
  Insufficient data on safety during lactation. Do not use.
  Action: Do not use while breastfeeding.
• hard stop — Gastroparesis
  Amylin analogues delay gastric emptying. Pre-existing gastroparesis creates risk of severe GI complications.
  Action: Do not use in patients with diagnosed gastroparesis. Refer to gastroenterologist.
• hard stop — Under 18 years of age
  Peptide protocols are not designed for pediatric use. Insufficient safety data in minors.
  Action: Do not provide peptide protocols to individuals under 18.
• requires physician — Insulin
  Concurrent use with insulin significantly increases risk of hypoglycemia. Amylin analogue activity slows gastric emptying and modulates glucagon, compounding insulin effects.
  Action: Do not initiate without physician supervision. Insulin dose reduction typically required. Frequent blood glucose monitoring mandatory.
• requires physician — Sulfonylureas
  Sulfonylureas stimulate insulin secretion independent of blood glucose. Combined with amylin analogue activity, hypoglycemia risk increases.
  Action: Physician must evaluate sulfonylurea dose reduction before initiating. Blood glucose monitoring required. Educate on hypoglycemia signs and management.
• monitor — Metformin
  Amylin analogue activity slows gastric emptying, which may alter metformin absorption kinetics. Additive gastrointestinal side effects possible.
  Action: Monitor for increased GI side effects. No dose adjustment typically required. Ensure adequate hydration. Monitor blood glucose during titration.
• requires physician — History of eating disorders
  Amylin analogue causes appetite suppression which may trigger eating disorder relapse.
  Action: Requires physician evaluation and mental health screening before initiation. Ongoing monitoring recommended.

Evidence

• Emerging pharmacotherapies for obesity: A systematic review

  Kokkorakis M, Chakhtoura M, Rhayem C, Al Rifai J, Ghezzawi M, Valenzuela-Vallejo L, Mantzoros CS (2025) — Pharmacol Rev — PMID: 39952695

  Incretin-based phase 2 trials show 7.4-24.2% mean weight loss. 14 ongoing phase 3 trials for next-generation agents. Retatrutide (GLP-1/GIP/glucagon triple agonist) and CagriSema (GLP-1/amylin) show greatest promise with potential for bariatric-surgery-level weight loss. Survodutide (GLP-1/glucagon RA) and orforglipron (oral GLP-1 RA) in phase 3. Oral semaglutide 50mg first oral agent to complete phase 3.

  strong

• Central nervous system pathways targeted by amylin in the regulation of food intake

  Hankir MK, Le Foll C (2024) — Biochimie — PMID: 39426704

  Cagrilintide (stable amylin analog) targets multiple CNS satiation circuits: nucleus tractus solitarius, area postrema, lateral parabrachial nucleus, VTA, arcuate and parasubthalamic nuclei. CagriSema (cagrilintide+semaglutide) synergistically lowers body weight in clinical trials via complementary CNS pathway engagement. Understanding distinct pathway recruitment is critical for minimizing adverse effects in dual/triple agonist therapies.

  moderate

Research Summary

TIER 1 (Human Clinical Trials): • Enebo et al. (2021, Lancet): Phase II dose-ranging study. Cagrilintide monotherapy at 4.5 mg weekly produced 10.8% body weight reduction at 26 weeks in adults with overweight/obesity (n=706). • CagriSema Phase II (Frias et al., 2023): Cagrilintide 2.4 mg + semaglutide 2.4 mg produced 15.6% weight loss at 20 weeks, exceeding semaglutide alone (5.1%) or cagrilintide alone (8.1%). Additive/synergistic effect confirmed. • REDEFINE Phase III program: Multiple ongoing trials evaluating CagriSema for obesity (REDEFINE 1), type 2 diabetes (REDEFINE 2), and other indications. TIER 2 (Limited Human / Strong Preclinical): • Pharmacokinetic studies establishing once-weekly dosing feasibility via acylation and albumin binding. • Amylin receptor characterization: Cagrilintide activates AMY1 and AMY3 receptor subtypes preferentially. • GI tolerability data showing nausea pattern consistent with amylin class effects. TIER 3 (Preclinical / Mechanistic): • Central satiety mechanism studies: Area postrema and NTS activation distinct from GLP-1R-mediated hypothalamic signaling. • Gastric emptying delay kinetics. • Glucagon suppression via amylin receptor activation in pancreatic alpha cells. EVIDENCE GAPS: Phase III results pending. Long-term safety (>1 year) not established. Cardiovascular outcome trial not initiated. Effect on lean body mass preservation not specifically studied. Comparison with pramlintide (existing amylin analog) not performed. Compounding/generic availability timeline unknown.